12V.F Veracyte Inc

Healthcare Biotechnology Frankfurt Exchange
21.50 EUR
Close of Nov 11, 2026
21.21 52.72
Market cap
EUR 1.73B
P/E
16.2x
P/B
1.43x
ROE
8.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 12V.F undervalued?

Graham number
Price21.50
Graham value21.18
Premium1.5%

12V.F trades 1.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Veracyte Inc fundamental analysis

No fundamental analysis for Veracyte Inc yet.

Veracyte Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system servic…

Full company profile